Solid Tumors

实体瘤

• 批准号: 6433369
• 负责人: LEE J. HELMAN
• 金额: --
• 依托单位: DIVISION OF CLINICAL SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/6433369
• 关键词: Ewing's tumor; T lymphocyte; alkylating agents; antigen presenting cell; cancer risk; child (0-11); clinical research; cytotoxicity; dosage; doxorubicin; human subject; human therapy evaluation; insulinlike growth factor; interview; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer relapse /recurrence; neoplasm /cancer vaccine; osteosarcoma; pediatric neoplasm /cancer; rhabdomyosarcoma; sarcoma; somatostatin; somatotropin

We have closed our previous high-risk sarcoma study and are hoping to open a new study in the next year. In collaboration with several other centers, we will studying a marrow purging approach using a monoclonal antibody and quantitative real time PCR (see Dr. Mackall's report). We have just closed our OncoLar. study in recurrent osteosarcoma and are currently finalizing the data for a paper. Briefly, the data demonstrate a 50% reduction in circulating IGFI levels with no changes in IGFBP3 levels or IGFII levels, an no further IGFI reduction with the addition of tamoxifen. No objective responses were seen. We have begun a new study for newly diagnosed localized and metastatic osteosarcoma patients in collaboration with several other centers. This study will attempt to determine the value of various new imaging techniques in predicting response to neoadjuvant chemotherapy as well as to prospectively perform gene expression profiling analysis on all tumors. It will also pilot the application of high-dose alkylating agent therapy with peripheral stem cell rescue for all metastatic patients and patients who demonstrate a poor histologic response to standard neoadjuvant therapy.

我们已经关闭了以前的高风险肉瘤研究，并希望在明年开设一项新研究。 与其他几个中心合作，我们将使用单克隆抗体和定量实时PCR研究骨髓清除方法（请参阅Mackall博士的报告）。 我们刚刚关闭了我们的coloral。在反复骨肉瘤中进行的研究，目前正在最终确定论文的数据。 简而言之，数据表明循环IGFI水平降低了50％，而IGFBP3水平或IGFII水平没有变化，而加入他莫昔芬则不会进一步降低IGFI。 没有看到客观的反应。 我们已经开始针对新诊断的局部和转移性骨肉瘤患者的新研究，并与其他几个中心合作。 这项研究将尝试确定各种新成像技术在预测对新辅助化疗的反应以及对所有肿瘤上的基因表达分析分析中的价值。 它还将针对所有转移性患者和患者对高剂量烷基化剂疗法的应用，以表现出对标准新辅助治疗的组织学反应不佳的患者。